Navigation Links
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Date:8/19/2007

ck their sugar levels should tell their doctor. The infusion of ORENCIA contains maltose, a sugar that can give falsely high blood glucose readings with some monitors on the day the infusion is received. The doctor may recommend a different monitor.

Women who are pregnant, planning to become pregnant or are thinking about becoming pregnant should tell their doctor. It is not known if ORENCIA(R) (abatacept) can harm an unborn baby. Women who are breast feeding should also inform their doctor. They will need to decide to either breast-feed or receive treatment with ORENCIA, but not both.

Important Information about Side Effects with ORENCIA

Like all medicines that affect your immune system, ORENCIA can cause serious side effects. The possible serious side effects include serious infections and allergic reactions. Also, rare cases of certain kinds of cancers have been reported.

People taking ORENCIA are at increased risk for developing infections including pneumonia, and other infections caused by viruses, bacteria, or fungi. Individuals should call their doctor immediately if they feel sick or get any infection during treatment with ORENCIA.

Allergic reactions are usually mild or moderate, generally occur within the first 24 hours of an infusion, and include hives, swollen face, eyelids, lips, tongue, throat, or trouble breathing. There have been some serious allergic reactions reported after receiving an infusion of ORENCIA.

There have been rare cases of certain kinds of cancer. The role of ORENCIA in the development of cancer is not known.

The more common side effects with ORENCIA are headache, upper respiratory tract infection, sore throat, and nausea.

For Full Prescribing Information, please visit http://www.ORENCIA.com or http://www.bms.com

Dosing and Administration

ORENCIA is administered by a healthcare pr
'/>"/>

SOURCE Bristol-Myers Squibb Company

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Materia Licenses Metathesis Catalyst Platform to Eisai
4. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
7. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
8. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
9. New Quality Control Systems for Every Laboratory Application
10. Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented
11. Antares Pharma Announces Positive Results from Application Site Study for Anturol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 ... specialty biotechnology company focused on developing aerosolized KL4 ... live teleconference and webcast at 8:30 a.m. Eastern Time ... management will discuss the 2015 second quarter financial ... company will issue a press release announcing the ...
(Date:8/3/2015)... REDWOOD CITY, Calif., Aug. 3, 2015 AcelRx ... company focused on the development and commercialization of innovative ... a business update and reported financial results for the ... Business highlights include: , On July 23, ... (CHMP) adopted a positive opinion for Zalviso™ for the ...
(Date:8/3/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest ... June 30, 2015. All comparisons, unless otherwise noted, are to ... Quarter 2015 Highlights include: , Revenue of $808 ... Total prescriptions dispensed of 234,000, an increase of 19% ... EBITDA of $22.7 million, an increase of 287% or $16.8 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
(Date:8/4/2015)... New York, NY (PRWEB) , ... August 04, 2015 , ... ... for the upcoming Pop & Rock Beauty Bash Tour. In addition, they have signed ... spokesperson. Lexi’s image will appear in forthcoming print and overall branding opportunities for the ...
(Date:8/4/2015)... ... ... More than 700 years of marital bliss were celebrated as 13 couples from Friendship ... Kafader and Richard Oas lead the non-denominational service for married couples wishing to reaffirm ... by the Moonlight Serenade Orchestra and a special honeymoon dinner featuring lobster and steak. ...
(Date:8/4/2015)... ... 2015 , ... Dr. Gary Richter, Montclair Veterinary Hospital, Oakland, ... contest is put on by the American Veterinary Medical Foundation (AVMF). , Dr. ... on community involvement, ethical behavior, passion for profession, and their connections to pets ...
(Date:8/4/2015)... Dallas, Texas (PRWEB) , ... August 04, 2015 , ... ... involved in allegedly defective medical device lawsuit claims dealing with Inferior Vena Cava Filters ... been filing the firm’s federal cases for Cook IVC Filter clients under In re ...
(Date:8/4/2015)... St. Louis, MO (PRWEB) , ... August 04, ... ... news, attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report ... documents.* Talcum powder lawyers provide regular news updates and cancer warning ...
Breaking Medicine News(10 mins):Health News:Rock Your Hair Signs On As Title Sponsor For The HYPE! Projects Pop & Rock Beauty Bash Tour 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4
... Will Earn Decision Resources, Gold Standard for Rheumatoid ... from Decision ResourcesWALTHAM, Mass., Jan. 28 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... on reducing the signs and symptoms of rheumatoid ...
... Data Show Significant Reduction In Snoring Events, Increase ... 28 AirWare, Inc., maker of Brez premium ... for inside the nose clinically proven to reduce ... bed partner, today announced availability in all Rite ...
... shows that very low amounts of Micromet,s EpCAM-targeting BiTE ... 28 Micromet, Inc. (Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune diseases, today announced ... Immunobiology describing in detail the mode of action ...
... BD (Becton, Dickinson and Company) (NYSE: BDX ... first fiscal quarter ended December 31, 2008, representing an increase ... quarter,s growth rate reflects the unfavorable impact from foreign currency ... percentage points. "BD is off to a solid start ...
... Inc. (Pink Sheets: PCIR) today announced it has entered ... spin off its wholly owned subsidiary, Prepaid Tel.com, Inc., ... firm which, once it has gone public, will reward ... company.The agreement with TransPacific Telecom, Inc., the developer of ...
... have delivered the world’s first commercially cloned dog, a 10-week old ... , ... Boca Raton, FL (Vocus) January 28, 2009 -- ... commercially cloned dog, a 10-week old Labrador named Lancey, to Florida ...
Cached Medicine News:Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 2Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 2Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 3Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 5Health News:BD Announces Results for First Fiscal Quarter 2Health News:BD Announces Results for First Fiscal Quarter 3Health News:BD Announces Results for First Fiscal Quarter 4Health News:BD Announces Results for First Fiscal Quarter 5Health News:BD Announces Results for First Fiscal Quarter 6Health News:BD Announces Results for First Fiscal Quarter 7Health News:BD Announces Results for First Fiscal Quarter 8Health News:BD Announces Results for First Fiscal Quarter 9Health News:BD Announces Results for First Fiscal Quarter 10Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:First Commercially Cloned Dog Delivered to Florida Family 2
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
For the quantitative in vitro determination of alanine aminotransferase in serum or plasma....
Medicine Products: